Berkeley Lights, Inc.

Bruker Cellular Analysis, Inc.

Bruker Cellular Analysic, Inc.

Guido K Stadler

Mark P White

Alexander J Mastroianni

Kevin T Chapman

Xiaohua Wang

Xiao Guan Radstrom

Randall D Lowe, Jr

Jason M McEwen

Gang F Wang

Minha Park

Peggy A Radel

Yelena Bronevetsky

George L Fox

Gregory G Lavieu

Peter J Beemiller

Natalie C Marks

Shao Ning Pei

Annamaria Mocciaro

Hansohl E Kim

Thomas M Vetterli

Vincent Haw Tien Pai

Jason M Mcewen

Amanda L Goodsell

John A Tenney

Duane Smith

Jr Randall D Lowe

Andrew W Mcfarland

Methods are provided for the assay of secreted biomolecules using automated detection and characterization of micro-objects in a microfluidic device. The biomolecules can be secreted by cells, particularly immunological cells, such as T cells. The biomolecules being assayed can include cytokines, growth factors, and the like. Methods are also provided for assaying the cytotoxicity of a cell with respect to another, target cell. Also provided are kits and non-transitory computer-readable media in which programs are stored for causing a system comprising a computer to perform automated methods for detecting secreted biomolecules and/or cytotoxicity in a microfluidic device.

Methods for assaying biological cells in a microfluidic device

A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.

Tumor infiltrating cells engineered to express a pro-inflammatory polypeptide

Growing community of inventors

San Francisco, CA, United States of America

Guido K Stadler